Allogene Therapeutics, Inc.

ALLO

Net income
-239
millions, $
Market cap
2.24
billions, $
EBITDA
-226
millions, $
Revenue
38.4
millions, $
P/E
N/A
Revenue Growth
N/A
% year on year
Dividends

Estimation

0
% per year
About

Allogene Therapeutics, Inc. operates as a biotechnology company. The company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors.

1. There may be a delay in updating the share price

The information on Dastocks.com is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy, or in any other way. Dastocks will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on the information on Dastocks.com. The Authors may buy and sell securities before and after any particular article and/or information herein is published.

You must accept the terms and conditions if you wish to continue to use the Dastocks website.